CervoMed Inc. Amends S-1 Filing for Warrant Placements

TL;DR

CervoMed filed S-1/A for warrant placements on 4/1/24. Check financials.

AI Summary

CervoMed Inc. filed an S-1/A on May 30, 2024, to amend its registration statement. The filing details a private placement of Series A Warrants and Prefunded Warrants that occurred on April 1, 2024. The company previously operated under the names Diffusion Pharmaceuticals Inc., RestorGenex Corp, and Stratus Media Group, Inc.

Why It Matters

This amendment provides updated information on CervoMed's capital raising activities, which could impact its financial structure and future operations.

Risk Assessment

Risk Level: medium — Amendments to S-1 filings often indicate ongoing or complex corporate actions, which can introduce uncertainty.

Key Numbers

• 20240530 — Filing Date (Date the S-1/A was filed with the SEC.)
• April 1, 2024 — Warrant Placement Date (Date of the private placement of Series A and Prefunded Warrants.)

Key Players & Entities

• CervoMed Inc. (company) — Filer of the S-1/A
• 0001053691 (company) — Central Index Key for CervoMed Inc.
• 20240530 (date) — Filing date of the S-1/A
• April 1, 2024 (date) — Date of private placement of warrants
• Diffusion Pharmaceuticals Inc. (company) — Former name of CervoMed Inc.
• RestorGenex Corp (company) — Former name of CervoMed Inc.
• Stratus Media Group, Inc (company) — Former name of CervoMed Inc.

FAQ

Key Financial Figures

• $0.001 — 0 shares of our common stock, par value $0.001 per share (the "Common Stock" or "commo
• $19.77 — e closing price of our Common Stock was $19.77. Investing in our securities involves
• $149.4 m — e gross proceeds of up to approximately $149.4 million, completed on April 1, 2024 401(
• $0 — mmon Stock the common stock, par value $0.001, of EIP issued and outstanding prio
• $21 million — al Institutes of Health NIA Grant the $21 million grant awarded to us by the NIA in Janua
• $39.24 — of common stock at a purchase price of $39.24 per share issued in connection with the
• $50.0 m — oceeds from the PIPE were approximately $50.0 million, before deducting offering fees a
• $99.4 million — l gross proceeds of up to approximately $99.4 million may be received if the Series A Warrant
• $21.0 million — study in patients with DLB funded by a $21.0 million grant from the NIA. We expect to comple
• $19.745 — eries A Warrant had a purchase price of $19.745 and a Unit comprised of one Pre-Funded
• $19.744 — eries A Warrant had a purchase price of $19.744. The 2024 Private Placement closed on A

Filing Documents

• crvo20240530c_s1a.htm (S-1/A) — 2645KB
• ex_681403.htm (EX-23.1) — 3KB
• cervomed01.jpg (GRAPHIC) — 11KB
• crvo20240508_s1img001.jpg (GRAPHIC) — 7KB
• crvo20240508_s1img002.jpg (GRAPHIC) — 26KB
• crvo20240508_s1img003.jpg (GRAPHIC) — 24KB
• crvo20240508_s1img004.jpg (GRAPHIC) — 19KB
• crvo20240508_s1img005.jpg (GRAPHIC) — 22KB
• crvo20240508_s1img006.jpg (GRAPHIC) — 12KB
• crvo20240508_s1img007.jpg (GRAPHIC) — 17KB
• crvo20240508_s1img008.jpg (GRAPHIC) — 24KB
• 0001437749-24-018760.txt ( ) — 10901KB
• crvo-20240331.xsd (EX-101.SCH) — 84KB
• crvo-20240331_def.xml (EX-101.DEF) — 700KB
• crvo-20240331_lab.xml (EX-101.LAB) — 357KB
• crvo-20240331_pre.xml (EX-101.PRE) — 738KB
• crvo-20240331_cal.xml (EX-101.CAL) — 57KB
• crvo20240530c_s1a_htm.xml (XML) — 1204KB

Risk Factors

Risk Factors 9 Cautionary Note Regarding Forward-Looking Statements 47

Use of Proceeds

Use of Proceeds 48 Market Information and Dividend Policy 49

Management's Discussion and Analysis and Results of Operations

Management's Discussion and Analysis and Results of Operations 50

Business

Business 58 Management 91 Executive and Director Compensation 100 Certain Relationships and Related Party Transactions 107

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 109 Selling Stockholders 111 Plan of Distribution 113

Description of Capital Stock

Description of Capital Stock 115 Legal Matters 119 Experts 119 Where You Can Find More Information 119 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission ("SEC"). As permitted by the rules and regulations of the SEC, the registration statement filed by us includes additional information not contained in this prospectus. You may read the registration statement and the other reports we file with the SEC at the SEC's website or its offices, as described below under the heading "Where You Can Find More Information". You should rely only on the information contained in this prospectus. We have not authorized any person to provide you with information different from that contained in this prospectus. This prospectus is not an offer to sell, nor is it seeking an offer to buy, these securities in any state where the offer or sale is not permitted. The information in this prospectus speaks only as of the date of this prospectus unless the information specifically indicates that another date applies, regardless of the time of delivery of this prospectus or of any sale of the securities offered hereby. Our business, financial condition, results of operations, and prospects may have changed since that date. We do not take any responsibility for, nor do we provide any assurance as to the reliability of, any information other than the information in this prospectus. Neither the delivery of this prospectus nor the sale of our Common Stock means that information contained in this prospectus is correct after the date of this prospectus. You should not consider this prospectus to be an offer or solicitation relating to the securities in any jurisdiction in which such an offer or solicitation relating to the securities is not authorized. Furthermore, you should not consider this prospectus to be an offer or solicitation relating to the securities if the person making the offer or solicitation i

Risk Factors

Risk Factors Investing in our securities involves risks. You should carefully consider the risks described in "Risk Factors" beginning on page 9 before making a decision to invest in our securities, as well as subsequent filings with the SEC. If any of these risks actually occurs, our business, financial condition and results of operations would likely be materially adversely affected. Some of the risks related to our business and industry are summarized below. The Company is a clinical stage company and has incurred significant losses since its inception. The Company expects its net losses to continue for the foreseeable future. The Company is not currently profitable and may never achieve or sustain profitability. The Company is unable to predict the extent of future losses or when it might become profitable, if ever. The Company will require additional capital to fund its operations. If the Company fails to obtain necessary financing on acceptab

View Full Filing

View this S-1/A filing on SEC EDGAR